undamentalytics Newsletter
Sign in

Organogenesis Holdings Inc. (ORGO) stock

Add to watchlist

Add holding +

NASDAQ: ORGO Nasdaq Health Care Supplies Next results ~November 5, 2026

D Fundamentals grade

Organogenesis Holdings Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$3.7

Revenue-to-maturity cash-flow model

Base case. Range ~$3.0–$4.5 across our lower- and higher-growth cases (1.5%–11.5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Organogenesis Holdings Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 1 selling2 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds84 adding, 46 cuttingOf 24 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Organogenesis files

Where Organogenesis stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $457m, up 6.5% on a year earlier, slower than the 12.2% growth a quarter earlier. Free-cash-flow margin rose to 4.6% from -10.8% a year earlier. Operating margin narrowed to -7.8% from -5.3%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 3 financial-health checks. Our revenue-to-maturity cash-flow model value is $3.66 a share, against a share price of $0.86.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Organogenesis Holdings Inc.'s trailing-twelve-month revenue grew 6.5% year on year, with a free-cash-flow margin of 4.6%. Where it stands out: gross margin of 75.9% ranks 2 of 13 health care supplies companies we cover. Where it lags: change in growth rate of -5.7pp ranks 11 of 13 health care supplies companies we cover.

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 98% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 5.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -7.8%: costs exceed revenue.
  • Volatile shares. Over the past year the shares showed annualised volatility of 79% and a beta of 1.3 against the S&P 500.
  • Below peers: change in share count. Change in share count of 1.7% ranks 10 of 12 health care supplies companies we cover (median 0.1%).
  • Below peers: days sales outstanding. Days sales outstanding of 81 days ranks 9 of 11 health care supplies companies we cover (median 65 days).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.69 against an average estimate of -$0.35: missed by 97.7%
Revenue
$44m, down 56.7% on a year earlier
Share reaction
-21.5% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.17

Organogenesis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+12.2%
  • 1 week-6.0%
  • 1 month-36.2%
  • This year-85.4%
  • 1 year-78.8%
  • 5 years-92.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$457M
Operating margin
-7.8%
Net margin
-18.4%
EPS (TTM, diluted)
$-0.64

Growth

Revenue growth
+6.5%
Change in growth rate
−5.7 pts
Share count change
+1.7%

Cash

Free cash flow (TTM)
$20.8M
FCF margin
4.6%
Stock pay % of revenue
3.1%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Organogenesis Holdings Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Organogenesis Holdings Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.86 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$3.7 ~$3.0–$4.5 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$4.9 ~$5.4–$11 Left out: out of range vs price (6.48x)
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$3.7 ~$3.0–$4.5 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Organogenesis Holdings Inc. with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201720182019202020212022202320242025Now
Share price$9.92$10.15$4.81$7.53$9.24$2.69$4.09$3.20$5.18$0.76
Market value$634m$704m$447m$839m$1.2bn$356m$543m$421m$675m$99m
+ Net debt (− = net cash)$55m$8m−$11m−$14m−$40m−$31m−$37m−$136m−$94m−$46m
Enterprise value$689m$711m$436m$824m$1.2bn$325m$506m$286m$581m$53m
Multiples
Price / sales 3.2x3.6x1.7x2.5x2.6x0.8x1.3x0.9x1.2x0.2x
Price / earnings ———48.7x13.1x22.9x109.8xn/m18.2x—
Price / free cash flow ————40.2x—82.9x100.9x—4.8x
EV / EBITDA ———26.5x15.3x11.5x22.0x23.2x9.7x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

56 /100

Moderate moat

How hard Organogenesis's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 12 / 20

    Cash operating profit has been a median 9.9% of total assets over 6 years.

  • Pricing power 18 / 20

    Gross margin has been a median 75.1%, moving by 3.7 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -5.3%; its worst year was -22.9%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 4 of 8 years, at a median -1.2% of revenue.

  • Discipline 15 / 20

    The diluted share count rose 4.1% over five years; stock-based pay has been a median 1.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (61 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $52m and EPS of −$0.17 (range −$0.17 to −$0.17) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.38 −425% $196m −65%
Next −$0.31 +77% $270m +38%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +85.8% on 90 days ago. In the last 30 days, 0 analysts raised Organogenesis Holdings Inc.'s forecast and 1 cut it.

Consensus EPS forecast Organogenesis Holdings Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.74 Current fiscal year, 60 days ago: −$0.82 Current fiscal year, 30 days ago: −$0.82 Current fiscal year, 7 days ago: −$0.82 Current fiscal year, Now: −$1.38 −$1.38 Next fiscal year, 90 days ago: −$0.23 Next fiscal year, 60 days ago: −$0.28 Next fiscal year, 30 days ago: −$0.28 Next fiscal year, 7 days ago: −$0.28 Next fiscal year, Now: −$0.31 −$0.31

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.74−$0.23
60 days ago −$0.82−$0.28
30 days ago −$0.82−$0.28
7 days ago −$0.82−$0.28
Now −$1.38−$0.31

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.35 −$0.69 −97.7%
Mar 2026 −$0.29 −$0.34 −18.0%
Dec 2025 $0.21 $0.40 +90.5%
Sept 2025 $0.07 $0.18 +153.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy00%
Hold2100%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202622

Counts of recommendations published by analysts covering Organogenesis Holdings Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
19.1%
of tradable shares
Days to cover
24.03
at average volume
Short interest, 1 month
+10%
to October 15, 2026
Held by institutions
52%
of shares
Held by insiders
44.6%
of shares
Employees
854
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −82.2%

$4.25 on October 31, 2025 to $0.76

ThenNowEffect
Revenue (last 12 months) $430m $457m +6.5%
P/S multiple 1.3x 0.2x −83.0%
Share count 129m 131m −1.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −68.1%

$2.37 on November 3, 2023 to $0.76

ThenNowEffect
Revenue (last 12 months) $457m $457m 0.0%
P/S multiple 0.7x 0.2x −68.6%
Share count 133m 131m +1.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ORGO+23%−71%+52%−22%+62%−85%
Industry peers (median)+13%−45%+22%−5%−20%−7%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ORGO42%25%42%42%67%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ORGO−61%−74%−56%−49%−57%−85%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since January 5, 2017: 100% from January 11, 2019 to November 2, 2026. Getting back needed a 19741% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.76 – $6.54
From 52-week high
−88.4%
vs 50-day average
−43.3%
vs 200-day average
−67.9%
Volatility (1 year)
79%
Beta vs S&P 500
1.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±25.7%
After a week
8 up, 4 down
typical move ±25.5%
After a month
7 up, 5 down
typical move ±22.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −21.5% +0.5% −25.7% −27.8%
May 7, 2026 −7.4% +0.5% +1.2% −7.0%
February 26, 2026 −21.9% −1.0% −29.4% −44.3%
November 6, 2025 +41.8% −1.0% +56.4% +17.4%
August 7, 2025 +1.2% +0.7% +4.4% +6.0%
May 8, 2025 −40.9% +0.6% −41.5% −33.6%
February 27, 2025 +91.1% −0.1% +73.4% +38.5%
November 12, 2024 +26.6% −0.3% +16.6% +0.9%
August 8, 2024 +2.0% +2.8% +0.8% +1.6%
May 9, 2024 +31.2% +0.7% +23.4% +15.2%
February 29, 2024 −16.3% +1.3% −10.3% −19.8%
November 9, 2023 +6.8% +0.8% +23.4% +57.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Organogenesis Holdings Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Organogenesis Holdings Inc.
$400M $450M $500M $550M $600M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $449M Revenue (TTM), FY23 Q4: $433.1M Revenue (TTM), FY24 Q1: $435.5M Revenue (TTM), FY24 Q2: $448.4M Revenue (TTM), FY24 Q3: $455M Revenue (TTM), FY24 Q4: $482M Revenue (TTM), FY25 Q1: $458.8M Revenue (TTM), FY25 Q2: $429.5M Revenue (TTM), FY25 Q3: $465.2M Revenue (TTM), FY25 Q4: $564.2M Revenue (TTM), FY26 Q1: $514.7M Revenue (TTM), FY26 Q2: $457.5M $457.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $449M
FY23 Q4 $433.1M
FY24 Q1 $435.5M
FY24 Q2 $448.4M
FY24 Q3 $455M
FY24 Q4 $482M
FY25 Q1 $458.8M
FY25 Q2 $429.5M
FY25 Q3 $465.2M
FY25 Q4 $564.2M
FY26 Q1 $514.7M
FY26 Q2 $457.5M
Revenue growth, TTM YoY Organogenesis Holdings Inc.
-10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -3.1% Revenue growth, TTM YoY, FY23 Q4: -3.9% Revenue growth, TTM YoY, FY24 Q1: -5.6% Revenue growth, TTM YoY, FY24 Q2: -2.0% Revenue growth, TTM YoY, FY24 Q3: 1.3% Revenue growth, TTM YoY, FY24 Q4: 11.3% Revenue growth, TTM YoY, FY25 Q1: 5.3% Revenue growth, TTM YoY, FY25 Q2: -4.2% Revenue growth, TTM YoY, FY25 Q3: 2.2% Revenue growth, TTM YoY, FY25 Q4: 17.0% Revenue growth, TTM YoY, FY26 Q1: 12.2% Revenue growth, TTM YoY, FY26 Q2: 6.5% 6.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -3.1%
FY23 Q4 -3.9%
FY24 Q1 -5.6%
FY24 Q2 -2.0%
FY24 Q3 1.3%
FY24 Q4 11.3%
FY25 Q1 5.3%
FY25 Q2 -4.2%
FY25 Q3 2.2%
FY25 Q4 17.0%
FY26 Q1 12.2%
FY26 Q2 6.5%
Operating margin (TTM) Organogenesis Holdings Inc.
-10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 5.0% Operating margin (TTM), FY23 Q4: 2.9% Operating margin (TTM), FY24 Q1: 2.9% Operating margin (TTM), FY24 Q2: -2.4% Operating margin (TTM), FY24 Q3: -2.8% Operating margin (TTM), FY24 Q4: -0.3% Operating margin (TTM), FY25 Q1: -5.3% Operating margin (TTM), FY25 Q2: -5.3% Operating margin (TTM), FY25 Q3: -1.8% Operating margin (TTM), FY25 Q4: 7.9% Operating margin (TTM), FY26 Q1: 0.5% Operating margin (TTM), FY26 Q2: -7.8% -7.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 5.0%
FY23 Q4 2.9%
FY24 Q1 2.9%
FY24 Q2 -2.4%
FY24 Q3 -2.8%
FY24 Q4 -0.3%
FY25 Q1 -5.3%
FY25 Q2 -5.3%
FY25 Q3 -1.8%
FY25 Q4 7.9%
FY26 Q1 0.5%
FY26 Q2 -7.8%
FCF margin (TTM) Organogenesis Holdings Inc.
-15% -10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -0.8% FCF margin (TTM), FY23 Q4: 1.5% FCF margin (TTM), FY24 Q1: 1.6% FCF margin (TTM), FY24 Q2: 1.9% FCF margin (TTM), FY24 Q3: 0.9% FCF margin (TTM), FY24 Q4: 0.9% FCF margin (TTM), FY25 Q1: -1.5% FCF margin (TTM), FY25 Q2: -10.8% FCF margin (TTM), FY25 Q3: -11.1% FCF margin (TTM), FY25 Q4: -4.3% FCF margin (TTM), FY26 Q1: 3.3% FCF margin (TTM), FY26 Q2: 4.6% 4.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -0.8%
FY23 Q4 1.5%
FY24 Q1 1.6%
FY24 Q2 1.9%
FY24 Q3 0.9%
FY24 Q4 0.9%
FY25 Q1 -1.5%
FY25 Q2 -10.8%
FY25 Q3 -11.1%
FY25 Q4 -4.3%
FY26 Q1 3.3%
FY26 Q2 4.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Organogenesis took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $564M
  2. Research and development $44.5M · 7.9%
  3. Selling, general and admin $326M · 57.8%
  4. Other operating costs $149M · 26.4%
  5. Operating income $44.7M · 7.9%
  6. Income tax $9.9M · 1.8%
  7. Net income $37M · 6.6%

Shares of revenue. Source: Organogenesis's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 139 199 193 261 338 467 451 433 482 564 457
Gross profit 91 137 125 185 251 353 346 327 366 — —
EBITDA −3 −2 −48 −26 31 78 28 23 12 60 −20
Operating income −9 −5 −52 −30 27 72 22 13 −1 45 −36
Net income −17 −8 −65 −39 17 94 16 5 1 37 −84
Diluted EPS −$0.27 −$0.14 −$0.94 −$0.42 $0.15 $0.70 $0.12 $0.04 −$0.01 $0.15 −$0.64
Growth (year on year)
Revenue — +43.1% −2.5% +34.9% +29.6% +38.2% −3.5% −3.9% +11.3% +17.0% +6.5%
EBITDA — — — — — +150.5% −63.9% −18.4% −46.3% +386.0% —
Operating income — — — — — +170.5% −69.1% −43.8% −110.2% — —
Net income — — — — — +446.6% −83.5% −68.2% — — —
Diluted EPS — — — — — +366.7% −82.9% −66.7% — — —
Margins
Gross margin 65.3% 69.2% 64.4% 70.9% 74.2% 75.6% 76.7% 75.4% 76.0% — —
EBITDA margin −2.2% −1.0% −24.9% −10.0% 9.2% 16.7% 6.2% 5.3% 2.6% 10.6% −4.4%
Operating margin −6.3% −2.8% −26.7% −11.4% 7.9% 15.5% 4.9% 2.9% −0.3% 7.9% −7.8%
Net margin −12.2% −4.2% −33.5% −14.8% 5.1% 20.2% 3.4% 1.1% 0.2% 6.6% −18.4%
Free-cash-flow margin −4.5% −3.0% −32.3% −15.1% −3.6% 6.6% −2.0% 1.5% 0.9% −4.3% 4.6%
Cash flow
Cash from operations −5 −3 −61 −34 5 62 25 31 14 −10 32
Capital spending 1 2 2 6 18 31 34 24 10 14 11
Free cash flow −6 −6 −62 −40 −12 31 −9 7 4 −24 21
Stock-based pay 0 1 1 1 2 4 7 9 11 13 14
Free cash flow after stock pay −7 −7 −64 −40 −14 27 −16 −2 −6 −38 7
Balance sheet
Cash 2 2 21 60 84 114 102 104 136 94 46
Total debt 0 57 29 50 70 74 71 67 0 0 0
Net debt (negative = net cash) −2 55 8 −11 −14 −40 −31 −37 −136 −94 −46
Diluted shares 63m 64m 69m 93m 111m 134m 132m 133m 132m 130m 131m
Returned to shareholders
Buybacks — — — — — — 0 0 25 — —
Total returned — — — — — — 0 0 25 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 3 checks passed · June 30, 2026
What it owns · $406m
Short-term assets $200mLonger-term assets $206m
What it owes, and who funded it · $267m
Short-term liabilities $57mLonger-term liabilities $61mShareholders' equity $148m
  • Short-term assets cover short-term liabilities $200m of assets due within a year against $57m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $200m short-term assets against $61m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$36m against −$1m of interest.

From Organogenesis Holdings Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.7%
year over year
R&D spending
12.5%
of revenue
Sales & admin spending
65.4%
of revenue
Days sales outstanding
81 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated ORGO UFPT MDXG EMBC OSUR ICUI Median
Revenue, last 12 months $457m $632m $304m $1.0bn $112m $2.2bn $1.0bn
Revenue growth, last 12 months 6.5% 7.3% −22.8% −7.6% −18.9% −9.0% 3.4%
Revenue growth, 3-year average 0.0% 17.8% −0.6% −2.9% −38.4% −2.0% 0.0%
Revenue growth, latest quarter −56.7% 15.1% −45.2% −8.1% −1.9% 0.5% 0.6%
Gross margin 75.9% 28.5% 77.3% 59.0% 42.6% 39.1% 52.9%
Operating margin −7.8% 15.3% −8.3% 21.9% −48.1% 3.3% 3.3%
Operating margin, 3-year average −5.2% 15.4% 8.0% 18.7% −28.5% 2.2% 2.2%
Net margin −18.4% 11.4% −6.3% 8.6% −43.7% 1.4% 1.4%
Cash from operations / revenue 7.0% 11.3% 6.8% 17.1% −38.1% 10.9% 10.6%
Free-cash-flow margin 4.6% 9.0% 2.0% 16.2% −42.8% 6.7% 6.7%
Free-cash-flow margin, 3-year average −1.4% 10.5% 11.2% 9.8% −8.5% 5.2% 9.8%
Stock pay / revenue 3.1% 1.6% 1.6% 2.5% 8.3% 2.5% 2.5%
Change in share count 1.7% 0.2% −0.9% 0.6% −4.9% 2.5% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth 6.5% 3.4% 4 of 13
Change in growth rate Growth -5.7pp -0.3pp 11 of 13
Gross margin Profitability 75.9% 52.9% 2 of 13
Operating margin Profitability -7.8% 3.3% 8 of 13
Net margin Profitability -18.4% 1.4% 10 of 13
Free-cash-flow margin Cash generation 4.6% 6.7% 8 of 13
Stock pay as % of revenue Cash generation 3.1% 2.5% 9 of 13
Change in share count Balance sheet 1.7% 0.1% 10 of 12
Days sales outstanding Balance sheet 81 days 65 days 9 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $563M 99.8% ▲ 16.8%
Grant $1.1M 0.2% —

From Organogenesis Holdings Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$166M
Institutions reporting
134
Shares held vs prior quarter
▲ 10.8%
Positions opened / closed
31 / 14

Top buyers and sellers, Q2 2026: 84 institutions bought and 46 sold ; the biggest buyer was Blackrock, Inc (+2.3M shares) and the biggest seller First Light Asset Management, LLC (−3.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Morgan Stanley $28.5M 11.7M 17.1% ▲ 0.9%
Soleus Capital Management, L.P. $24.6M 10.1M 14.8% ▲ 0.5%
Blackrock, Inc. $17.6M 7.2M 10.6% ▲ 48.0%
Assenagon Asset Management S.A. $9.6M 3.9M 5.8% ▲ 100.0%
Dimensional Fund Advisors LP $7.4M 3.1M 4.5% ▲ 5.5%
AQR Capital Management LLC $7.3M 3.0M 4.4% ▲ 241.6%
Vanguard Capital Management LLC $7.1M 2.9M 4.2% ▲ 0.2%
D. E. Shaw & Co., Inc. $7M 2.9M 4.2% ▲ 25.7%
Geode Capital Management, LLC $4.7M 1.9M 2.8% ▲ 8.5%
Deutsche Bank Ag\ $4.1M 1.7M 2.5% 0.0%
Vanguard Portfolio Management LLC $3.9M 1.6M 2.4% ▲ 10.9%
Acadian Asset Management LLC $3.7M 1.5M 2.3% ▼ 2.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Organogenesis Holdings Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $40,100 2 trades by 2 insiders, last 12 months Insider sales History → $2.6M 4 trades by 1 insider · 0% under pre-set plans
Net ▼ $2.6M net selling
Insider Date Trade Shares Price Value
Driscoll Michael Joseph Director March 9, 2026 Buy 10,000 $2.67 $26,700
Leibowitz Arthur S Director March 9, 2026 Buy 5,000 $2.68 $13,400
Nussdorf Glenn H Director December 16, 2025 Sell 200,000 $5.14 $1M
Nussdorf Glenn H Director November 26, 2025 Sell 187,957 $5.29 $994,293
Nussdorf Glenn H Director November 25, 2025 Sell 12,043 $5.30 $63,828
Nussdorf Glenn H Director November 24, 2025 Sell 100,000 $5.34 $534,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Organogenesis Holdings Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Organogenesis Holdings Inc. in brief

What does Organogenesis Holdings Inc. do?
Organogenesis Holdings Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.
What is Organogenesis Holdings Inc.'s stock ticker?
Organogenesis Holdings Inc. trades under the ticker ORGO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Organogenesis Holdings Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Organogenesis Holdings Inc. reported revenue of $457M, 6.5% higher than a year earlier, according to its SEC filings.
What is Organogenesis Holdings Inc.'s free cash flow?
Organogenesis Holdings Inc.'s free-cash-flow margin is 4.6% of revenue over the trailing twelve months, ranking 8 of the 13 health care supplies companies we cover.
Who are Organogenesis Holdings Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Morgan Stanley, Soleus Capital Management, L.P. and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Organogenesis Holdings Inc.'s market cap?
On November 2, 2026, Organogenesis Holdings Inc.'s market capitalisation was about $99.1M and net debt of -$46.1M. Market figures come from third-party market data and may be delayed.
Who are Organogenesis Holdings Inc.'s competitors?
In our Health Care Supplies peer group, the companies closest to Organogenesis Holdings Inc. are UFP Technologies Inc, Mimedx Group, Inc., Embecta Corp., Orasure Technologies Inc and ICU Medical Inc. The side-by-side comparison below sets their revenue, margins and growth against Organogenesis Holdings Inc.'s.
Are insiders buying or selling Organogenesis Holdings Inc. stock?
Over the last 12 months, Organogenesis Holdings Inc.'s directors and officers reported 2 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Organogenesis Holdings Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Organogenesis Holdings Inc. announces its own schedule.